Drug interactions
Indacaterol-glycopyrronium + Osimertinib
Severity: Moderate
Indacaterol-glycopyrronium and Osimertinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Osimertinib is associated with QTc prolongation, and indacaterol may add to cardiac repolarisation effects, particularly if potassium is low. The combination may raise the risk of ventricular arrhythmias.
What this interaction means in plain words
Indacaterol-glycopyrronium and Osimertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Indacaterol-glycopyrronium belongs to Respiratory; Osimertinib belongs to Oncology.
Why it happens
Additive QT interval prolongation with potential beta-agonist induced hypokalemia.
What to do
Monitor ECG and electrolytes periodically and correct potassium and magnesium deficits. Reassess therapy if QTc becomes markedly prolonged or the patient has arrhythmic symptoms.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Osimertinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Osimertinib
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Osimertinib?
MediHelp rates the interaction as moderate. Indacaterol-glycopyrronium and Osimertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Osimertinib is associated with QTc prolongation, and indacaterol may add to cardiac repolarisation effects, particularly if potassium is low. The combination may raise the risk of ventricular arrhythmias.
How serious is the interaction between Indacaterol-glycopyrronium and Osimertinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes periodically and correct potassium and magnesium deficits. Reassess therapy if QTc becomes markedly prolonged or the patient has arrhythmic symptoms.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
